'The abrupt no-flow': A no-reflow like phenomenon in hypertrophic cardiomyopathy [5]

European Heart Journal

Volumn 23, Issue 1, 2002, Pages 91-93

  Kuhn, H ^a   Gietzen, F ^a   Leuner, C ^a  

^a OWL University   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALCOHOL; GLYCERYL TRINITRATE; MIDAZOLAM; VERAPAMIL;

ANGIOCARDIOGRAPHY; CATHETER ABLATION; COLOR ULTRASOUND FLOWMETRY; CORONARY ARTERY BLOOD FLOW; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; LETTER; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; CORONARY CIRCULATION; CORONARY VESSELS; HUMANS;

EID: 0036403095     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2944     Document Type: Letter

References (14)

1. Cuccurullo F, Mezzetti A, Lapenna D et al. Mechanisms of isoproterenol-induced angina pectoris in patients with obstructive hypertrophic cardiomyopathy and normal coronary arteries. Am J Cardiol 1987; 60: 667-73.
2. Dimitrow PP, Krzanowski M, Nizankowski R, Szczeklik A, Dubiel JS. Comparison of the effect of verapamil and propranolol on response of coronary vasomotion to cold pressor test in symptomatic patients with hypertrophic cardiomyopathy. Cardiovasc Drugs Ther 2000; 14: 643-50.
3. Kuhn H, Seggewiss H, Gietzen F et al. Catheter interventional therapy for HOCM: First two year analysis of the National Registry of the German Cardiac Society. Eur Heart J (Abstr Suppl) 2000; 21: 413.
4. Kim JJ, Lee CW, Park SW et al. Improvement in exercise capacity and exercise blood pressure response after transcoronary alcohol ablation therapy of septal hypertrophy in hypertrophic cardiomyopathy. Am J Cardiol 1999; 83: 1220-3.
5. Kuhn H, Gietzen F, Leuner CH, Gehrenkamp T. Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Studies to develop a new catheter based concept of treatment. Eur Heart J 1997; 18: 846-51.
6. Kuhn H, Gietzen FH, Leuner CH et al. Transcoronary ablation of septal hypertrophy (TASH): A new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 2000; 89 (Suppl 4): 41-54.
7. Olivotto I, Maron BI, Montereggi A, Mazzuoli F, Dolora A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999; 33: 2044-51.
8. Limbruno U, Strata G, Zucchi R et al. Altered autonomic cardiac control in hypertrophic cardiomyopathy. Eur Heart J 1998; 19: 146-53.
9. Meirhaeghe A, Bauters C, Helbecque N et al. The human G-protein β3 subunit C825T polymorphism is associated with coronary artery vasoconstriction. Eur Heart J 2001; 22: 845-8.
10. Shirani J, Pick R, Roberts WC, Maron BI. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35: 36-44.
11. Bishop N, Rees MR. Idiosyncratic reaction to intracoronary injection of non-ionic contrast media. Clin Radiol 1988; 39: 396-7.
12. Mauser M, Dittmann H, Voelker W, Kühlkamp V, Karsch KR. Occlusive spasm of the left coronary artery during coronary angiography. Z Kardiol 1990; 79: 654-8.
13. Laskey W, Boyle J, Johnson L and the Registry Committee of the Society for Cardiac Angiography and Interventions. Multivariable model for prediction of risk of significant complication during diagnostic cardiac catheterization. Cath Cardiovasc Diagnosis 1993; 30: 185-90.
14. Wu DJ, Ueng KC, Lin CS et al. Multivessel spasm during coronary angiographic procedure in catheterization laboratory. Acta Cardiologica Sinica 1999; 15: 45-50.